SCHEMBL31072452

SCHEMBL31072452

NCCN1CCC(CC(=O)O)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT3 O60678 1/20 0.49
CARM1 Q86X55 1/20 0.49
PRMT6 Q96LA8 1/20 0.49
PRMT1 Q99873 1/20 0.49
PRMT8 Q9NR22 1/20 0.49
GNAI3 P08754 2/20 0.46
GNAO1 P09471 2/20 0.46
GNAI1 P63096 2/20 0.46
ALOX15 P16050 1/20 0.44
ANPEP P15144 1/20 0.40
ENPEP Q07075 1/20 0.40
CHRM3 P20309 1/20 0.37
SLC6A1 P30531 2/20 0.37
GABRA5 P31644 2/20 0.37
GABRB2 P47870 2/20 0.37
SLC6A12 P48065 2/20 0.37
SLC6A11 P48066 2/20 0.37
SLC6A13 Q9NSD5 2/20 0.37
GABRA1 P14867 1/20 0.37
GABRR1 P24046 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20366141 0.81 PRMT3 (0.46) PRMT3CARM1PRMT6PRMT1PRMT8
SCHEMBL13934478 0.81 SMN1; SMN2 (0.46) GNAI3GNAO1GNAI1
SCHEMBL25133751 0.79 CYP1A2 (0.40) CHRM3SLC6A1GABRA5GABRB2SLC6A12
Oxalic Acid SCHEMBL9345651 0.79 PRMT3 (0.47) PRMT3CARM1PRMT6PRMT1PRMT8
SCHEMBL7327464 0.78 EPHX1 (0.47) GNAI3GNAO1GNAI1CHRM3
SCHEMBL12155298 0.77 CACNA1I (0.48) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
SCHEMBL23533551 0.77 KCNH2 (0.51) GNAI3GNAO1GNAI1
SCHEMBL4270988 0.77 CYP2D6 (0.53) PRMT3CARM1PRMT6PRMT1PRMT8
SCHEMBL17430744 0.77 ARG1 (0.44) ANPEPENPEP
Hydrochloric Acid SCHEMBL23533426 0.77 GNAO1 (0.47) GNAI3GNAO1GNAI1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4648849-A1 NMU RECEPTOR 2 AGONISTS Boehringer Ingelheim International GmbH (DE) 2025-11-19 EP claimed
US-20240279278-A1 NMU RECEPTOR 2 AGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-08-22 US claimed
WO-2024149820-A1 NMU RECEPTOR 2 AGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-07-18 WO claimed
EP-4648849-A1 NMU RECEPTOR 2 AGONISTS Boehringer Ingelheim International GmbH (DE) 2025-11-19 EP disclosed
WO-2024149820-A1 NMU RECEPTOR 2 AGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240279278-A1 NMU RECEPTOR 2 AGONISTS NMUR2, NMUR1, NMBR PRMT3 1564/4885CARM1 3609/4885PRMT6 1916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.